RxDoctor Payments Data

Shinu Varghese

Optometrist · Darien, ILNPI 1437281920

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.3% of the total across 20 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Coopervision Inc. accounts for 80.4% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2024 at $191 and has fallen 64.7% since, to $68 in 2025. That places this record below the midpoint for optometrist clinicians in IL, where the typical reported total is $552.

$647in general payments, 2019–2025

Across 20 payments — averaging $32.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coopervision Inc.$520
  • Tarsus Pharmaceuticals, Inc.$34
  • Carl Zeiss Meditec, Inc.$33
  • Alcon$24
  • Carl Zeiss Meditec AG$19
  • Bausch & Lomb Americas Inc.$16
$15,420in research payments, 2019–2025

Across 4 payments — averaging $3855.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Coopervision Inc.$15K

What the payments were for

  • Food & beverage$61094%
  • Gifts$376%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$647 in reported general payments places this provider in the 50th percentile of 2,257 optometrist providers in Illinois.

See all optometrist providers in Illinois

Medicare billing

Part B allowed, 2024
$32,952
Medicare patients
164
Services billed
397

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Latanoprost51$930
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha15$120

Paid to pharmacies, not to this prescriber.

Other optometrist in Darien

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →